A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

Completed · Phase 3 · NCT06067230

Conditions: Respiratory Syncytial Virus

Research payments reported, 2025: $4.4M
U.S. investigators named: 33
Sites paid: 27
Planned or actual enrollment: 1,153

About the trial

Sponsor: ModernaTX, Inc.
Tested: mRNA-1345 (biological)
Dates: Started 2023-10-06; completion 2026-07-24
Results posted: Not yet

The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to \<60 years. Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received solid organ transplant (SOT).

From ClinicalTrials.gov, last updated 2026-08-20. Full record, eligibility and contacts (opens in a new tab)

Industry funding

ModernaTX, Inc. reported $4.4M in research payments for this study in 2025 (672 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it